Back to Newsroom

Novavax to Present Clinical Data on RSV F and NanoFlu™ Vaccines at World Vaccine Congress

GAITHERSBURG, Md., April 02, 2018 (GLOBE NEWSWIRE) — Novavax, Inc., (Nasdaq:NVAX) today announced it will present on its two lead vaccine programs at the World Vaccine Congress, April 2-5 in Washington, D.C. These presentations include details from the Phase 3 Prepare™ trial of its RSV F vaccine for infants via maternal immunization, as well as positive results from the Phase 1/2 trial of NanoFlu recombinant influenza vaccine, including its proprietary Matrix-M™ adjuvant, in older adults.
READ MORE…